Looking to the Future With Hope: Advances in the Treatment of AML

Looking to the Future With Hope: Advances in the Treatment of AML

On-Demand Webcast

Mojtaba Akhtari, MD
Keck School of Medicine of USC
Los Angeles, California

Daniel A. Pollyea, MD, MS
University of Colorado School of Medicine
Denver, Colorado

Target Audience

This activity is intended for hematologists, medical oncologists, and other healthcare professionals (physicians, nurse practitioners, physician assistants, pharmacists, etc.) who are involved and/or interested in the treatment of patients with acute myeloid leukemia.


Acute myeloid leukemia (AML) represents a significant clinical management challenge, as its overall prognosis is dismal, with low response rates to traditional therapy. Clinicians encounter many treatment challenges in AML, especially among high-risk patient populations and those with relapsed or refractory (R/R) disease. The need for effective and safe treatment alternatives to traditional therapy for these patient populations is urgent. Fortunately, important strides toward effective treatments for AML have been made recently, with several new targeted treatments and a liposomal chemotherapy treatment approved in the last 2 years. Such recent and rapid changes in the AML treatment landscape requires education on new clinical data and expert guidance to facilitate the clinical integration of these changes.

This on-demand webcast addresses the educational gaps among healthcare professionals pertaining to targeted treatment options for AML.


Upon successful completion of this educational activity, participants should be better able to:

  1. Explain how cytogenetics and molecular markers testing should be used to define risk status and inform treatment in patients with AML
  2. Discuss optimal positioning of novel agents in treatment approaches for AML based on current data
  3. Integrate the latest clinical trial data and expert knowledge surrounding novel AML interventions and adverse event management into therapeutic clinical decisions
  4. Engage in patient communication strategies to address barriers to AML clinical trial enrollment for increased awareness and acceptance of emerging therapies

Release Date: April 30, 2019

Expiration Date: April 30, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


Supported by an educational grant from AbbVie, Inc.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.75 contact hour.


This knowledge-based activity (UAN: JA0006201-9999-20-018-H01-P) is approved for 0.75 contact hours (0.0075 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Mojtaba Akhtari, MD and Daniel A. Pollyea, MD, MS; and Chris Bolwell and Monalisa Singh, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Mojtaba Akhtari, MD has received Grant/Research support from Amgen. He has also been a speaker for Adios, Amgen, Celgene, Incyte, Jazz, and Novartis.

Daniel A. Pollyea, MD, MS has acted as a consultant for AbbVie, Agios, Astellas, Celgene, Daiichi Sankyo, Gilead, and Pfizer. He has received Grant/Research support from AbbVie, Inc.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.